NovoCure Limited (NASDAQ:NVCR) reached 126.97% versus a 1-year low price of $19.06. The stock was last seen 2.98% higher, reaching at $43.25 on 01/11/2019. At recent session, the prices were hovering between $41.5 and $43.27. This company shares are 4.62% off its target price of $45.25 and the current market capitalization stands at $3.91B. The recent change has given its price a 31.04% lead over SMA 50 and -19.46% deficit over its 52-week high. The stock witnessed 22.04% gains, -3.76% declines and 29.69% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found NVCR’s volatility during a week at 6.62% and during a month it has been found around 6.09%.NovoCure Limited (NVCR) Top Holders
Institutional investors currently hold around $2.34 billion or 68.6% in NVCR stock. Look at its top three institutional owners. Fmr Llc owns $469.06 million in NovoCure Limited, which represents roughly 12% of the company’s market cap and approximately 20.09% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 5,424,908 shares of the stock are valued at $234.63 million. The third largest holder is Blackrock Inc., which currently holds $205.44 million worth of this stock and that ownership represents nearly 5.25% of its market capitalization.NovoCure Limited 13F Filings
At the end of September reporting period, 97 institutional holders increased their position in NovoCure Limited (NASDAQ:NVCR) by some 10,338,966 shares, 74 decreased positions by 8,462,355 and 20 held positions by 35,176,711. That puts total institutional holdings at 53,978,032 shares, according to SEC filings. The stock grabbed 34 new institutional investments totaling 1,419,652 shares while 16 institutional investors sold out their entire positions totaling 3,635,413 shares.NovoCure Limited (NASDAQ:NVCR) Insider Trades
Multiple company employees have indulged in significant insider trading. NovoCure Limited disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Commercial Officer Shah Pritesh has sold 8,988 shares of NovoCure Limited (NVCR) in trading session dated Jan. 09, 2019. These shares are worth $359,520 and were traded at $40 each. The SEC filing shows that Ambrogi Michael J. performed a sale of 100,000 shares. The COO disposed these shares by way of transaction on Jan. 09, 2019. The company’s shares were given away at $40 per share worth to an income of some $4,000,000 on account of Ambrogi Michael J..
General Counsel, Longsworth Todd Christopher, sold 15,000 common shares of NovoCure Limited (NVCR) in the open market. In a transaction dated Jan. 09, 2019, the shares were put up for sale at an average price of $40.15, raking in a sum of $602,250. After this sale, 21,305 common shares of NVCR are directly owned by the insider, with total stake valued at $921,441.
In the transaction dated Jan. 09, 2019, the great number of shares disposed came courtesy the Director; Leung Gabriel disposed a total of 20,000 shares at an average price of $40, amounting to approximately $800,000. The insider now directly owns 60,000 shares worth $2,595,000.NovoCure Limited (NVCR) Analyst Guide
Several analysts have released their opinion on NovoCure Limited (NASDAQ:NVCR), with 1 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.